CLRPF (Clarity Pharmaceuticals) Common Stock : $89.42 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Common Stock?

Clarity Pharmaceuticals's quarterly common stock declined from Dec. 2022 ($89.48 Mil) to Jun. 2023 ($89.14 Mil) but then increased from Jun. 2023 ($89.14 Mil) to Dec. 2023 ($89.42 Mil).

Clarity Pharmaceuticals's annual common stock increased from . 20 ($0.00 Mil) to Jun. 2022 ($92.84 Mil) but then declined from Jun. 2022 ($92.84 Mil) to Jun. 2023 ($89.14 Mil).

Clarity Pharmaceuticals Common Stock Historical Data

The historical data trend for Clarity Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Common Stock Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Jun24

Common Stock

92.84

89.14

165.64

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Common Stock	Get a 7-Day Free Trial			92.84	89.48	89.14	89.42	165.64

Clarity Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Clarity Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

CU6:Australia

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States.